BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
BNB$577.36-1.84%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
BNB$577.36-1.84%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
Vanda stock jumped more than 40% in premarket trading after the FDA approved its new drug BYSANTI for Bipolar I disorder and schizophrenia.
Moderna stock dropped over 9% in premarket trading after the FDA refused to review its mRNA-based flu vaccine, citing inadequate study design.
Novo Nordisk stock jumped 8% after Hims & Hers withdrew its knockoff Wegovy pill amid FDA scrutiny and legal threats.
Novo Nordisk shares rose more than 7% in premarket trading after the FDA approved its oral Wegovy weight-loss pill.
Moderna shares fell over 4% after the FDA signaled stricter vaccine approval rules, raising concerns about potential delays for new vaccines.
Biohaven dropped 44% in premarket trading after the FDA declined to approve Vyglxia, citing issues with trial design even as data showed slower disease progression.
Outlook Therapeutics stock crashed 70% in premarket after the FDA rejected its wet AMD drug application, citing insufficient efficacy evidence despite previous trial successes.
Shares of drugmaker Ars Pharmaceuticals crashed over 57% after FDA disapproved its EpiPen alternative.
How will the rally end?